Synonym
CX-157; CX157; CX 157; TriRima; Tyrima;
IUPAC/Chemical Name
3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
InChi Key
PDIMOTRDGUQMNY-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2
SMILES Code
FC(F)(F)COC1=CC(OC2=CC(F)=CC=C2S3(=O)=O)=C3C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
348.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fowler JS, Logan J, Azzaro AJ, Fielding RM, Zhu W, Poshusta AK, Burch D, Brand B, Free J, Asgharnejad M, Wang GJ, Telang F, Hubbard B, Jayne M, King P, Carter P, Carter S, Xu Y, Shea C, Muench L, Alexoff D, Shumay E, Schueller M, Warner D, Apelskog-Torres K. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31. doi: 10.1038/npp.2009.167. PubMed PMID: 19890267; PubMed Central PMCID: PMC2833271.
2: Burch D, Asgharnejad M, Gerson W, Fielding RM, Azzaro AJ. Lack of tyramine pressor response effect with oral CX157: A specific reversible MAOI. Clin Pharmacol Drug Dev. 2014 Jan;3(1):4-12. doi: 10.1002/cpdd.61. PubMed PMID: 27128224.
3: Targum SD, Burch DJ, Asgharnejad M, Petersen T, Gomeni R, Fava M. Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients. Eur Neuropsychopharmacol. 2014 Aug;24(8):1188-95. doi: 10.1016/j.euroneuro.2014.06.003. PubMed PMID: 25012515.
4: Targum SD, Pendergrass JC, Toner C, Asgharnejad M, Burch DJ. Audio-digital recordings used for independent confirmation of site-based MADRS interview scores. Eur Neuropsychopharmacol. 2014 Nov;24(11):1760-6. doi: 10.1016/j.euroneuro.2014.08.016. PubMed PMID: 25239474.
